Enhancing tumor cell response to chemotherapy through nanoparticle-mediated codelivery of siRNA and cisplatin prodrug

Cisplatin and other DNA-damaging chemotherapeutics are widely used to treat a broad spectrum of malignancies. However, their application is limited by both intrinsic and acquired chemoresistance. Most mutations that result from DNA damage are the consequence of error-prone translesion DNA synthesis,...

Full description

Bibliographic Details
Main Authors: Xu, Xiaoyang (Contributor), Xie, Kun (Contributor), Zhang, Xue-Qing (Author), Pridgen, Eric M. (Contributor), Park, Ga Young (Contributor), Cui, Danica S. (Author), Shi, Jinjun (Author), Kantoff, Philip W. (Author), Lippard, Stephen J. (Contributor), Walker, Graham C. (Contributor), Farokhzad, Omid C. (Author), Langer, Robert S (Author), Wu, Jun (Author)
Other Authors: Massachusetts Institute of Technology. Department of Biology (Contributor), Massachusetts Institute of Technology. Department of Chemical Engineering (Contributor), Massachusetts Institute of Technology. Department of Chemistry (Contributor), Koch Institute for Integrative Cancer Research at MIT (Contributor), Langer, Robert (Contributor)
Format: Article
Language:English
Published: National Academy of Sciences (U.S.), 2014-08-28T15:36:57Z.
Subjects:
Online Access:Get fulltext